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Iron, Copper, Zinc, Magnesium, and Calcium in 
Postmortem Brain Tissue from Schizophrenic Patients 
Johannes Kornhuber, Klaus W. Lange, Paul Kruzik, Wolf-Dieter Rausch, 
Eberhard Gabriel, Kurt Jellinger, and Peter Riederer 
The regional distribution of iron, copper, zinc, magnesium, and calcium in postmortem brain of 
schizophrenic patients was compared with that of matched controls. In none of the brain 
regions investigated (caudate nucleus, hippocampus, amygdala, cortex, corpus mamillare, 
gyrus cinguli, and hypothalamus) were significant differences observed between these two 
groups. In the total group, region-specific differences were found for iron, copper, zinc, and 
calcium, but not for magnesium. Gender differences were observed only for zinc. There was no 
correlation between a neuroleptic-free p riod before death and the content of any of the metals 
investigated, except for a positive correlation between copper in the hippocampus and a 
neuroleptic-free p riod. The results of the present study suggest that there are no profound 
differences in the content of iron, copper, zinc, magnesium, and calcium in postmortem brains 
between controls and schizophrenic patients. 
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Introduction 
Transition metals uch as iron, copper, and zinc are known 
to play a cmcial role in various physiological functions in 
mammalian brains, for example, in prosthetic groups of 
metalloenzymes and in the control of gene expression 
(O'Halloran 1993). Transition metals have been linked pri- 
marily to neurological disorders uch as Wilson's disease, 
Hallervorden-Spatz syndrome, Parkinson's disease and 
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Alzheimer's disease (e.g., Riederer et al 1989; Constantin;- 
dis 1991; Good et al 1992). C,~,sidvfing the c~tical rote of 
transition metals in enzyme and receptor function, however, 
excess or deficiency of these lements might also be related 
to the pathophysiology of schizophrenia. 
Zinc is unevenly distributed within the brain with partic- 
ularly high concentrations in the hippocampal mossy fiber 
system, where it acts as a neuromodulator (Xie and Smart 
1991). Interactions with inhibitory (Smart and Constanti 
1990) and excitatory amino acid neurotransmission (Yet et 
a11990) are well known. Although low to moderate concen- 
trations of zinc attenuate N-methyl-o-aspartate (NMDA)- 
mediated and enhance quisqualate-mediated n urotoxicity 
(Koh and Choi 1988), high concentrations of zinc are neur- 
otoxic (Yokoyama et al 1986). Zinc deficiency has been 
hypothesized tobe an important factor in the pathogenesis 
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of schizophrenia (Kimura and Kumura 1965; Pfeiffer and 
lliev 1972; Andrews 1990). 
Enhanced concentrations of zinc could be linked to the 
pathophysiology of schizophrenia, too. The glutamate hy- 
pothesis of schizophrenia proposes that a deficiency in glu- 
tamatergic neurotransmission and a resulting disturbance in 
balance between glutamatergic and dopaminergic systems 
within the ba~l ganglia may play a key role in the patho- 
physiology of schizophrenia (Kim et al 1980; Komhuher et 
al 1989a). Zinc inhibits transmission at the NMDA receptor 
(Yeh et al 1990). Enhanced activity of zinc at the NMDA 
receptor might thus be involved in the pathophysiology of 
schizophrenia. Results of direct measurements of zinc in 
human postmortem brain tissue are inconsistent. Kimura 
and Kumura (1965) found a 50% decrease in the zinc con- 
centration in the hippocampus of schizophrenic patients and 
McLardy (1973) found a 30% reduction in zinc content in 
the brains of patients with early onset schizophrenia. 
Greiner et al (1975) found no differences in zinc content in 
several brain regions, however, the hippocampus was not 
investigated by these authors. No consistent differences in
the content of zinc were found in cerebrospinal fluid (Potkin 
et al 1982) or plasma (Gillin et al 1982) of schizophrenic 
patients. 
There are several findings linking schizophrenia to dis- 
turbed iron metabolism. Iron exerts aprofound influence on 
dopaminergic neurotransmission a d behavior in labora- 
tory animals (Yehuda and Youdim 1988). Low serum iron 
levels were reported in patients uffering from neuroleptic- 
induced side effects, that is, akathisia (Brown et al 1987) 
and neuroleptic malignant syndrome (Rosebush and Ma- 
zurek 1991). Some investigators had the impression of in- 
creased iron staining in postmortem brain sections (Josephy 
1930; Stevens 1982). Recently, iron was quantified inpost- 
mortem brains from schizophrenic patients using optical 
density measurements of coronal sections tained with the 
Pearl's technique (Casanova etai 1992). In that study stain- 
lag intensity of iron was significantly increased in the can- 
date nucleus, which was attributed to neuroleptic therapy. 
The main support for a copper hypothesis ofschizophre- 
nia comes from repeated findings of elevated copper and 
coeruloplasmin concentrations in the serum of schizo- 
phrenic patients (Bowman and Lewis 1982). Several cop- 
per-dependent enzymes are involved in catecholamine m - 
tabolism. More recent investigations, however, found 
unchanged copper levels in plasma nd urine (Gillin et al 
1982), cerebrospinal fluid (Shore et al i983), and brain 
(Greiner et al 1975) of schizophrenic patients. 
Besides the above-mentioned transition metals, changes 
in calcium and magnesium levels have also been linked to 
the pathophysiology of schizophrenia (Alexander and Jack- 
son 1981 ). Direct measurements of these metals in postmor- 
tem human brain tissue have revealed no significant abnor- 
malities in schizophrenia (Greiner et a11975), however. The 
aim of the present study is to assess the content of iron, 
copper, zinc, magnesium, and calcium in several brain re- 
gions of schizophrenic patients and controls. 
Materials and Methods 
Postmortem handling of the autopsy materi~ was similar in 
all cases. Brains were obtained at autopsy from ! 2 subjects 
(!0 women, 2men) with no history of neurological orpsy- 
chiatric disorders. Control subjects had a mean age of 
75.3 +- 7.1 years (_ SD, range 41-91 years). This group 
was compared to ! I schizophrenic patients (6 women, 5 
men) diagnosed according to both Feighner et ai (1972) and 
to the International Classification of Diseases (1CD-9). 
These patients had a mean age of 69.6 +_ 8.2 years (range 
57-80 years). The diagnostic subgroups according to the 
ICD-9 were schizophrenia simplex (ICD 295.0, n = I), 
hebephrenic subtype (ICD 295. !, n = I), paranoid subtype 
(ICD 295.3, n = i), chronic schizophrenia (ICD 295.6, n = 
7), and schizoaffective psychosis (ICD 295.7, n = !). ~;e- 
cause there may be racial difference in the metabolism of 
certain metals (Potkin et al 1982), only brain specimens 
from Caucasian patients were investigated. Histopathologi- 
cal examination was performed on all brains to exclude 
other abnormalities such as rumor, infarction, anoxia, brain 
atrophy, and Alzheimer's disease. Postmortem delay time 
(i.e., time between death and freezing) was less than 24 hr in 
all cases. A detailed examination fcase notes was made to 
establish whether the patients had received neuroleptic 
medication during the period leading up to death. Three 
patients had been drug-free for at least 1 year and 7 patients 
were drug free for at least 3 months. Putamen samples from 
all the schizophrenic patients and three of the controls had 
previously been analyzed for [3H]spiperone binding (Korn- 
huber et al 1989b). Brain tissue was taken from the caudate 
nucleus, hippocampus, amygdala, cortex, corpus mamil- 
lare, ~/rus cinguli, and hypothalamus from both hemi- 
spheres. It was not possible to collect samples of all seven 
regions from every brain (Table 1) The tissue was quickly 
frozen and stored at -70°C until analysis 
Iron, copper, zinc, magnesium, and calcium were deter- 
mined by an atomic absorption procedure (Stevens 1970). 
Thawed tissue was freeze-dried at -60°C and 10-: T for 24 
hr. Thereafter, the dry tissue was weighed and dissolved in 
acid-washed vials with I ml of 65% nitric acid p.a. at ! 10°C. 
The evaporated dry residue was taken up into 5 ml of the 
diluent. Atomic absorption spectroscopy was performed 
using a Zeiss PMQ II photometer. 
Results are expressed as micrograms per gram dry 
weight. Mean values are given + SD. Nonparametric statis- 
tics (Mann-Whitney U-test, Fisher's exact probability test, 
Spearman's rank correlation, Kruskal-Wallis one-way 
ANOVA) were used throughout sing the two-tailed ap- 
proach. P-values higher than 0.05 were regarded as not 
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Table I. Case Data and Results of Metal Analysis in Postmortem Human Brains of Schizopluenic Patients (S) and Commh (C) 
Gender Iron Copper Zinc Magnegum 
n MhF Age (yrs) F~g &Y weight 
Cak4.Utlm 
Caudme nucleus C 9 I/8 72.7 -+ 14.7 450.9 +- 167.6 26.0 -*- 6.6 67.2 + 17.5 589.2 +- 126A 265.3 +- 2342 
S I I  5/6 69.6"--8.2 384.9"-- 139.2 24.9-+5.8 59.5--- 15.5 584.6-83.1 247.1 --.212.7 
Hippocampus C 8 I/7 76.6 - 9.3 221.9 -+ 42.7 18.0 -+ 3A 86.3 -+ 13.0 556-2 +- 172.1 368.9 "-. 210.3 
S 9 4/5 70.8 -+ 7.6 207.5 ± 27.3 19.9 -+ 4.0 83.8 +- 10.2 582.4 *- 147.2 ~67o0 _ !10.8 
Amygdala C 9 I/8 75 .6 -  + 15.1  221.'/-+57.8 .)0.6"-- 11-2 73.2"-- 15.5  1370.5"-.2458 259.5"-- 164.6 
S I I 5/6 69.6 -+ 8.2 211.6 +- 45.7 18.8 -+ 4.2 72.9 -+ 14.6 541.0 +- 174.5 219.9 ± 89.7 
Cortex C 3 I/2. 75.0 + 10.0 219.7 -+ 13.0 23.0 +- 5.3 76.2 -+ 9.4 734.7 -+ 51.5 610.0 ± 223.6 
S 7 314 68.9 ± 8.6 195.9 -+ 24.2 22.5 +- 2.7 73.5 -+ 9.4 612.4 +- 133.9 492.4 -+ 285.1 
Cmpusmamillar¢ C 5 114 77.0-+ 10.6 303.2 -+ 122.1 19.0-+ 2.1 44.4-+9.5 483.0-+ 176.3 495.4-+ 118.8 
S 5 ~3 67.6 -+ 10.2 251.6 ± 54.4 24.1 -+ 4.9 59.9 ± 14.3 625.6 -+ 106.6 450.6 -+ 171.2 
Gyms cinguli C 5 114 78.8 ± 8.8 166A ± 48.5 20.6 ± 2.2 58.9 ± 22.0 604.2 ± 80.6 337.6 ± 93.4 
S 6 ~4 68.5-+9.4 235.8-+ 111.3 21A ± 2.9 75.5-+ 15.7 664.7±43.8 516.3-+232.2 
H~vodmlamus C 4 0/4 78.5 -+ 9.3 160.4 -+ 58.7 23.2 +- 7.0 44.5 ± 10.4 625.8 -+ 285A 714.5 ± 891.6 
S 5 114 71.0 ± 8.0 290.2 ± 170.5 23.2 +- 6.7 60.3 ± 16.2 450.0 ± 64.8 1173.0 -+ 1766.5 
Tic, me ~mple~ from the different region.~  not m~ilable from all brains. 
Theeefome. the case data te lisled for each region ~parately. Mean values me given -+ SD. 
No differences inthe COmlem of an), of the five metals between controls and ~hizophrenic patients were observed (Mann-Whitney U-le~ p > 0.05). 
Table 2. Effect ,~f B~'.m Region on Metal Concentration 
(by KruskaLWallis One-Way ANOVA) 
Iron Copper Zinc Magnesium Calcium 
Controls ¢ NS ¢ NS NS 
Schizophrenics ,, NS b NS 
Total Group c e, ~ NS ¢ 
NS = no~ significant. ,'p < 0.05. bp < 0.01. ~p < 0.001. 
significant. Because of the explorative nature of the study, 
no et-conectious were applied. 
Results 
Data on case histories and results are given in Table 1. Age 
and gender were not significantly different between con- 
trois and schizophrenic patients. When the control and 
©rhiT,-u~hm~nio or~**n~ worp  enmnared  nn  differences inthe 
~amm~iTguwaua~ ~.  v~j -~ . . . . . . . . . . .  r ~ - - ~  . . . . . . . .  
content of any ofth~ five metals investigated were observed 
(Table 1). 
Looking at the total group (controls and schizophrenics 
combined), magnesium was distributed homogeneously in 
the seven brain regions investigated (Table 2), but there 
were significant regional differences for the other metals. 
For iron and copper, we found higher concentrations i  the 
caudate nucleus than ;.n ~he hl.ppoca.mp~Js and amygdala. 
Zinc concentrations were highest in the hippocampus, with 
decreasing values in the amygdala nd candate nucleus 
(Table !). 
The effect of gender was investigated for each brain 
region using the total group (controls and schizophrenics) 
and the schizophrenic subgroup, respectively. The low 
number of men in the controls did riot allow a meaningful 
comparison i this group. Except for zinc, none of investi- 
gated metals were significantly different in men compared 
to women, either in the total group or in schizophrenics 
(data not shown). In the total group there was a gender 
difference in zinc content only in the hippocamp~ (76.2 + 
6.2 in men versus 88.6 + 10.6 in women, itg/g dry weight. 
p < 0.01). In schizophrenic patients, there was a gender 
difference inthe caudate nucleus (47.6 + 12.3 in men versus 
65.9 _+ 13.1 in women, ixg/gdryweight,p < 0.05) and in the 
hippocampus (77.1 -+ 6.8 in men versus 88.3 --- 8.8 in 
women, ixg/g dry weight, p < 0.05). There was no correla- 
tion between the neumleptic-free p riod before death and 
the content of any of the metals investigated, except ~or a 
positive correlation between copper and the neuroleptic- 
free period in the hippocampus (r = 0.83, p < 0.02). One 
schizophrenic female aged 77 years had suffered from tar- 
dive dyskinesia before death. In this patient, he contents of 
all metals investigated were within the mean _ 2 SD range 
of schizop,hrenic patients widumt ardive dyskinesi~ 
Discussion 
The metal concentrations and the regional distributions 
found in this study we, re generally in accordance with 
previous investigations onhuman brain material (Harrison 
et al 1968; Vi~lkl and Ule i 972; Ule et ai ! 974; Riederer et al 
1989). In none of the brain regions investigated significant 
differences were observed between schizophrenics and 
controls. Because a number of the patients will have re- 
ceived long-term anfipsychotic drug treatment, it is con- 
ceivable that this may have had an effect on the content of 
the metals investigated. Theoretically, a preexisting differ- 
ence in the metal content could have been masked by neuro- 
leptic drugs. Except for the copper content in the hippocam- 
pus, however, the neuroleptic-free time before death ad no 
impact on the metal concentrations. The functional signifi- 
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cance of the positive correlation between copper level and 
neuroleptic-free time before death should not be over-inter- 
preted because of the explorative nature of the study (no 
a-corrections were applied). 
Taken together, the results of the present study show that 
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